Evaluation of carbamazepine pharmacokinetic profiles in mice with kainic acid-induced acute seizures

Biological and Pharmaceutical Bulletin

Volumn 31, Issue 12, 2008, Pages 2302-2308

  Nishimura, Asako ^a   Honda, Naoki ^b   Sugioka, Nobuyuki ^b   Takada, Kanji ^b   Shibata, Nobuhito ^a  

^a DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Antiepileptic drug; Brain distribution; Carbamazepine; Kainic acid induced seizure; P glycoprotein

Indexed keywords

CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; GLYCOPROTEIN P; KAINIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; MALE; MOUSE; NONHUMAN; PROTEIN FUNCTION; SEIZURE; TISSUE DISTRIBUTION; WESTERN BLOTTING;

ACUTE DISEASE; ANIMALS; ANTICONVULSANTS; BLOTTING, WESTERN; BRAIN; CARBAMAZEPINE; COLORING AGENTS; DATA INTERPRETATION, STATISTICAL; DRUG RESISTANCE; EXCITATORY AMINO ACID AGONISTS; INFUSIONS, INTRAVENOUS; INTESTINES; KAINIC ACID; MALE; MICE; P-GLYCOPROTEIN; PERFUSION; PROTEIN BINDING; REFERENCE STANDARDS; RHODAMINE 123; SEIZURES; SOLUTIONS;

EID: 57349191684     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.31.2302     Document Type: Article

References (22)

1. Regesta G., Tanganelli P., Epilepsy Res., 34, 109-122 (1999).
2. Weiss J., Kerpen C. J., Lindenmaire H., Dormann S. G., Haefeli W. E., J. Pharmacol. Exp. Ther., 307, 262-267 (2003).
3. Spector R., Pharmacology, 60, 58-73 (2000).
4. Silverman J. A., Pharm. Biotechnol., 12, 353-386 (1999).
5. Fromm M. F., Int. J. Clin. Pharmacol. Ther., 38, 69-74 (2000).
6. Habgood M. D., Begley D. J., Abbott N. J., Cell Mol. Neurobiol., 20, 231-253 (2000).
7. Potschka H., Fedrowitz M., Loscher W., Neuroreport, 12, 3557-3560 (2001).
8. Owen A., Pirmohamed M., Tettey J. N., Morgan P., Chadwick D., Park B. K., Br. J. Clin. Pharmacol., 51, 345-349 (2001).
9. Baltes S., Gastens A. M., Fedrowitz M., Potschka H., Kaever V., Löscher W., Neuropharmacology, 52, 333-346 (2007).
10. Langer O., Bauer M., Hammers A., Karch R., Pataraia E., Koepp M. J., Abrahim A., Luurtsema G., Brunner M., Sunder-Plassmann R., Zimprich F., Joukhadar C., Gentzsch S., Dudczak R., Kletter K., Müller M., Baumgartner C., Epilepsia, 48, 1774-1784 (2007).
11. Bouër R., Barthe L., Philibert C., Tournaire C., Woodley J., Houin G., Fundam. Clin. Pharmacol., 13, 494-500 (1999).
12. Kageyama M., Fukushima K., Togawa T., Fujimoto K., Taki M., Nishimura A., Ito Y., Sugioka N., Shibata N., Takada K., Biol. Pharm. Bull., 29, 779-784 (2006).
13. Rizzi M., Caccia S., Guiso G., Richichi C., Gorter J. A., Aronica E., Aliprandi M., Bagnati R., Fanelli R., D'Incalci M., Samanin R., Vezzani A., J. Neurosci., 22, 5833-5839 (2002).
14. Schinkel A. H., Wagenaar E., Mol C. A., van Deemter L., J. Clin. Invest., 97, 2517-2524 (1997).
15. Watkins P. B., Adv. Drug Deliv. Rev., 27, 161-170 (1997).
16. Löscher W., Potschka H., NeuroRx, 2, 86-98 (2005).
17. Potschka H., Fedrowitz M., Löscher W., Neurosci. Lett. , 327, 173-176 (2002).
18. Kwan P., Sills G. J., Brodie M. J., Pharmacol. Ther., 90, 21-34 (2001).
19. Rane A., Wilkinson G. R., Shand D. G., J. Pharmacol. Exp. Ther., 200, 420-424 (1977).
20. Giessmann T., May K., Modess C., Wegner D., Hecker U., Zschiesche M., Dazert P., Grube M., Schroeder E., Warzok R., Cascorbi I., Kroemer H. K., Siegmund W., Clin. Pharmacol. Ther., 76, 192-200 (2004).
21. Emoto C., Yamazaki H., Yamasaki S., Shimada N., Nakajima M., Yokoi T., Xenobiotica, 30, 943-953 (2000).
22. Contin M., Riva R., Albani F., Perucca E., Lamontanara G., Baruzzi A., Eur. J. Clin. Pharmacol., 29, 211-214 (1985).